{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', 'ART drug regimen(s) that participants started after withdrawal from the main', 'study due to meeting CVW or PVW criteria', 'Plasma HIV-1 RNA levels after regimen switch and up to 12 months after CVW', 'or PVW date', 'Reasons for virologic failure when the subsequent treatment regimen is changed', 'nonadherence, tolerability, adverse event, etc.', 'Reasons for switching when the subsequent treatment regimen is changed', '-', 'virologic failure, tolerability, safety, adherence, convenience, etc.', 'Adverse Events, SAEs or Death leading to ARV discontinuation', 'Adverse Drug Reactions, SAEs or Death related to ViiV Healthcare products', 'Pregnancy while on ViiV Healthcare products', 'Concomitant Medications', 'Schedule of Activities', 'Procedures', 'Baseline (after', '3 months', '6 months', '12', 'regimen switch', 'months', 'upon withdrawal', 'from 208090 main', 'study)', 'Written Informed Consent', 'X', 'Current ART regimen', 'X', 'X', 'X', 'X', 'Plasma HIV-1 RNA (if available)', 'X', 'X', 'X', 'X', 'Reasons for Virologic Failure', 'X', 'X', 'X', 'Reasons for Switch (if subsequent', 'X', 'X', 'X', 'regimen is changed)', 'Adverse Events, SAEs, or Death', 'X', 'X', 'X', 'X', 'leading to ARV discontinuation', 'Adverse Drug Reactions, SAEs, or', 'X', 'X', 'X', 'X', 'Death related to ViiV Healthcare', 'products', 'Pregnancy while on ViiV Healthcare', 'X', 'X', 'X', 'X', 'products', 'Concomitant Medications', 'X', 'X', 'X', 'X', 'a.', 'Investigator must collect pregnancy information on the appropriate form and submit to ViiV/GSK/PPD', '91']['2017N331008_06', 'CONFIDENTIAL', '208090', 'Since this sub-study is an observational study of participants who have withdrawn from', 'the main study, the protocol-specified withdrawal and stopping criteria are not applicable.', '11.2.4.', 'Sub-study data Collection', 'For this study, participant data will be entered into eCRFs, transmitted electronically to', 'GSK or designee and supplemented with demographic and clinical data provided from', 'the 208090 study in a validated data system.', 'Management of clinical data will be performed in accordance with applicable PPD', 'standards and data cleaning procedures to ensure the integrity of the data, e.g. removing', 'errors and inconsistencies in the data.', 'Adverse events, SAEs and concomitant medications terms will be coded using MedDRA', 'and an internal validated medication dictionary, GSKDrug.', 'eCRFs (including queries and audit trails) will be retained by GSK, and copies will be', 'sent at the end of the study in CD format to GSK to be retained. Each investigator will', 'receive a copy of his or her site-specific data in the same format to maintain as the', 'investigator copy. Participant initials will not be collected or transmitted to ViiV', 'Healthcare/GSK according to ViiV Healthcare/GSK policy.', '11.2.5.', 'Statistical Considerations and Data Analysis', 'This is a descriptive study. No formal hypothesis will be tested. Where possible,', 'frequency tables will be provided.', 'The endpoint assessing the proportion of participants with plasma HIV-1 RNA <50', 'copies/mL, 50-200 copies and >200 copies/mL at the end of 12 months will be based on', 'an observed case analysis for this descriptive study.', 'Further details will be provided in the RAP.', '92']['2017N331008_06', 'CONFIDENTIAL', '208090', '11.3.', 'Appendix 3: Toxicity Management', 'Adverse events that occur during the trial should be evaluated by the investigator and', 'graded according to the DAIDS toxicity scales (see Section 11.11). Additional', 'information regarding detecting, documenting and reporting AEs and SAEs are available', 'in Section 11.8.', 'Study intervention may be interrupted at the discretion of the investigator and according', 'to the severity of the AE. If one or more ART medication is held due to toxicity or AEs,', 'all ART medications should be held to reduce the risk of development of resistance', 'taking into account the length of the planned interruptions and the PK half-life of each', 'ART of the regimen, in order to minimize the risk of development of resistance.', 'No toxicity-related dose reductions of study interventions will be allowed. Study', 'interventions should be restarted as soon as medically appropriate; in general, this should', 'be no longer than 4 weeks after interruption (unless Grade 3 or 4 toxicities persist).', 'Decisions regarding sequential reintroduction of study interventions or temporary', 'interruption of one but not all drugs within the ART regimen should be made with the', 'understanding that these changes may result in incomplete viral suppression and selection', 'of resistant virus. Guidance is provided below on participant management and study', 'intervention interruptions based on the severity of the AE for specific toxicities. All', \"changes in study intervention must be accurately recorded in the participant's eCRF.\", 'Grade 1 or Grade 2 Toxicity/Adverse Event', 'Participants who develop a Grade 1 or Grade 2 AE or toxicity may continue study', 'intervention at the discretion of the investigator. Participants who choose to withdraw', 'from the study due to a Grade 1 or 2 AE should have study withdrawal and follow-up', 'evaluations completed.', 'Grade 3 Toxicity/Adverse Event', 'Participants who develop a Grade 3 AE or toxicity should be managed as follows:', 'If the investigator has compelling evidence that the Grade 3 AE or toxicity has not been', 'caused by study intervention, dosing may continue after discussion with the medical', 'monitor.', 'Participants who develop a Grade 3 AE or toxicity that the investigator considers related', 'or possibly related to the interventions should have study intervention withheld and be', 'rechecked each week until the AE returns to Grade 2. Once the AE is Grade 2, study', 'intervention may be restarted.', 'Should the same Grade 3 AE recur within 28 days in the same participant, study', 'intervention should be permanently discontinued and the participant withdrawn from', 'study. Participants experiencing Grade 3 AEs requiring permanent discontinuation of', 'study intervention should be followed weekly until resolution of the AE and have', 'withdrawal study evaluations completed. A Follow-up visit should be performed', '4 weeks after the last dose of study interventions.', '93']\n\n###\n\n", "completion": "END"}